摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(2-羟基-4-硝基苯基)乙酰胺 | 25351-89-7

中文名称
N-(2-羟基-4-硝基苯基)乙酰胺
中文别名
N-(2-羟基-4-硝基苯基)乙酰胺;N-(2-羟基-4-硝基苯基)-乙酰胺
英文名称
N-(2-hydroxy-4-nitrophenyl)acetamide
英文别名
2-acetamido-5-nitrophenol;2-acetylamino-5-nitrophenol;3-nitro 6-acetylamino phenol;5-nitro-2-acetaminophenol;acetic acid-(2-hydroxy-4-nitro-anilide);Essigsaeure-(2-hydroxy-4-nitro-anilid)
N-(2-羟基-4-硝基苯基)乙酰胺化学式
CAS
25351-89-7
化学式
C8H8N2O4
mdl
MFCD00219839
分子量
196.163
InChiKey
VVVCUZJRBFEICS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    258-259 °C
  • 沸点:
    436.1±40.0 °C(Predicted)
  • 密度:
    1.477±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    95.2
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2924299090
  • 储存条件:
    存储条件:2-8°C,需密封并保持干燥。

SDS

SDS:625a2e07429c41696f9bff5551fce0da
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

点击查看最新优质反应信息

文献信息

  • Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity
    作者:Hwei-Ru Tsou、Elsebe G. Overbeek-Klumpers、William A. Hallett、Marvin F. Reich、M. Brawner Floyd、Bernard D. Johnson、Ronald S. Michalak、Ramaswamy Nilakantan、Carolyn Discafani、Jonathan Golas、Sridhar K. Rabindran、Ru Shen、Xiaoqing Shi、Yu-Fen Wang、Janis Upeslacis、Allan Wissner
    DOI:10.1021/jm040159c
    日期:2005.2.1
    inhibitor 86 (EKB-569). Three synthetic routes were used to prepare these compounds. They were prepared mostly by acylation of 6-amino-4-(arylamino)quinoline-3-carbonitriles with unsaturated acid chlorides or by amination of 4-chloro-6-(crotonamido)quinoline-3-carbonitriles with monocyclic or bicyclic anilines. The third route was developed to prepare a key intermediate, 6-acetamido-4-chloroquinoline-3-carbonitrile
    一系列新的6,7-二取代的4-(芳基氨基)喹啉-3-甲腈衍生物可作为人类表皮生长因子受体2(HER-2)和表皮生长因子受体(EGFR)激酶的不可逆抑制剂发挥作用。准备好了。与我们的EGFR激酶抑制剂86(EKB-569)相比,这些化合物表现出增强的抑制HER-2激酶和HER-2阳性细胞生长的活性。使用三种合成途径来制备这些化合物。它们的制备主要是通过6-氨基-4-(芳基氨基)喹啉-3-腈与不饱和酰氯的酰化作用或通过4-氯-6-(巴豆酰胺基)喹啉-3-腈与单环或双环苯胺的胺化而制备的。开发了第三条路线来制备关键中间体,即6-乙酰氨基-4-氯喹啉-3-腈,该中间体涉及更安全的环化步骤。我们显示,在4-(芳基氨基)环的对位上附加一个大的亲脂基团会导致抑制HER-2激酶的效力提高。我们还显示了在迈克尔受体末端的碱性二烷基氨基对于活性的重要性,这归因于迈克尔加成的分子内催化作用。这与改善的水溶性一起
  • Protein tyrosine kinase enzyme inhibitors
    申请人:Wissner Allan
    公开号:US20050059678A1
    公开(公告)日:2005-03-17
    This invention provides compounds of formula 1, having the structure wherein R 1 , R 2 , R 3 , R 4 , and R 5 are described within the specification.
    本发明提供了具有以下结构的公式1化合物,其中R1、R2、R3、R4和R5在说明书内描述。
  • Compounds which can be used for hair dyeing, process for their
    申请人:L'Oreal
    公开号:US04888025A1
    公开(公告)日:1989-12-19
    The present invention relates to new 1-(substituted phenoxy)-3-aminopropan-2-ol compounds in which the extra-nuclear amine group may or may not be substituted, and to the process for their preparation. The invention also relates to hair-dyeing compositions containing these new compounds and to a dyeing process using the said compositions.
    本发明涉及新的1-(取代苯氧基)-3-氨基丙-2-醇化合物,其中额外的非核胺基团可能被取代,也可能不被取代,以及它们的制备过程。该发明还涉及含有这些新化合物的染发剂组合物以及使用所述组合物的染发过程。
  • [EN] COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY<br/>[FR] COMPOSES PRESENTANT UNE AFFINITE AVEC LE RECEPTEUR 5HT2C ET UTILISATION THERAPEUTIQUE DE CEUX-CI
    申请人:GLAXO GROUP LTD
    公开号:WO2003089409A1
    公开(公告)日:2003-10-30
    Compounds of formula (I) or a pharmaceutically acceptable salt thereof are disclosed: wherein R1 is hydrogen, hydroxy, fluoro, chloro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy or haloC1-6alkoxy; m is 0 when ======= is a double bond and m is 1 when ======= is a single bond; R2 is hydrogen, halogen, cyano, nitro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1-6alkylthio, amino, mono- or di-C1-6alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is -(CH2-CH2)-, -(CH=CH)-, -(CH2)3-, -C(CH3)2-, -(CH=CH-CH2)-, -(CH2-CH=CH)- or a group -(CHR5)- wherein R5 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy or C1-6alkylthio; R3 is halogen, cyano, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy, C1-6alkylthio, hydroxy, amino, mono- or di-C1-6alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC1-6alkyl, haloC1-6alkoxy, aryl, arylC1-6alkyl, arylC1-6alkyloxy, arylC1-6alkylthio or COOR6, CONR7R8 or COR9 wherein R6, R7, R8 and R9 are independently hydrogen or C1-6alkyl; p is 0, 1 or 2 or 3; R4 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C1-6alkanoyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1-6alkylthio, amino, mono- or di-C1-6alkylamino or an N-linked 4 to 7 membered heterocyclic group; Y is oxygen, sulfur, -CH2- or NR10 wherein R10 is hydrogen or C1-6alkyl; D is a single bond, -CH2-, -(CH2)2- or -CH=CH-; and Z is an optionally substituted C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, an optionally substituted N-linked 4 to 7 membered heterocyclic group, or Z is -NR11R12 where R11 and R12 are independently hydrogen or C1-6alkyl. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression and anxiety, are also disclosed.
    公式(I)的化合物或其药学上可接受的盐被披露:其中R1是氢,羟基,氟,氯,C1-6烷基,C3-7环烷基,C3-7环烷氧基,C1-6烷氧基或卤代C1-6烷氧基;当=======是双键时,m为0,当=======是单键时,m为1;R2是氢,卤素,氰基,硝基,C1-6烷基,C3-7环烷基,C3-7环烷氧基,卤代C1-6烷基,C1-6烷氧基,卤代C1-6烷氧基,C1-6烷硫基,氨基,单或双C1-6烷基氨基或N-连接的4至7成员杂环基;X是-(CH2-CH2)-,-(CH=CH)-,-(CH2)3-,-C(CH3)2-,-(CH=CH-CH2)-,-(CH2-CH=CH)-或一个基团-(CHR5)-其中R5是氢,卤素,羟基,氰基,硝基,C1-6烷基,C3-7环烷基,C3-7环烷氧基,卤代C1-6烷基,C1-6烷氧基,卤代C1-6烷氧基或C1-6烷硫基;R3是卤素,氰基,C1-6烷基,C3-7环烷基,C3-7环烷氧基,C1-6烷氧基,C1-6烷硫基,羟基,氨基,单或双C1-6烷基氨基,N-连接的4至7成员杂环基,硝基,卤代C1-6烷基,卤代C1-6烷氧基,芳基,芳基C1-6烷基,芳基C1-6烷氧基,芳基C1-6烷硫基或COOR6,CONR7R8或COR9其中R6,R7,R8和R9独立地是氢或C1-6烷基;p是0,1,2或3;R4是氢,卤素,羟基,氰基,硝基,C1-6烷基,C1-6烷酰基,C3-7环烷基,C3-7环烷氧基,卤代C1-6烷基,C1-6烷氧基,卤代C1-6烷氧基,C1-6烷硫基,氨基,单或双C1-6烷基氨基或N-连接的4至7成员杂环基;Y是氧,硫,-CH2-或NR10其中R10是氢或C1-6烷基;D是单键,-CH2-,-(CH2)2-或-CH=CH-;Z是含有至少一个氮的可选择取代的C-连接的4至7成员杂环基,可选择取代的N-连接的4至7成员杂环基,或Z是-NR11R12其中R11和R12独立地是氢或C1-6烷基。还披露了其制备方法和在治疗中的用途,特别是用于中枢神经系统疾病如抑郁症和焦虑症。
  • [EN] SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS<br/>[FR] UTILISATION DE QUINOLINES SUBSTITUEES COMME INHIBITEURS DE LA TYROSINE KINASE
    申请人:WYETH CORP
    公开号:WO2005034955A1
    公开(公告)日:2005-04-21
    This invention provides compounds of formula (I), having the structure wherein R1, R2, R3 are described within the specification. The compounds act as anti-cancer agents by inhibition of HER-2 and EGFR.
    这项发明提供了一种具有公式(I)的化合物,其结构式中R1、R2、R3在说明书中有描述。这些化合物通过抑制HER-2和EGFR起到抗癌剂的作用。
查看更多